The Winning Technology of Prize4Life's $1M Biomarker Prize to Be
Evaluated in New Research Study
In 2011, Prize4Life awarded its $1M ALS Biomarker Prize to Dr. Seward Rutkove for his discovery of a biomarker for ALS - a technology
called electrical impedance myography (EIM). EIM sensitively measures the flow of a small
electrical current through muscle tissue. The current travels differently
through healthy and diseased tissue, and by comparing the size and speed of the
electrical current, EIM can accurately measure ALS progression. EIM is
non-invasive and totally painless and involves only the application of a small
sensor pad to a muscle and the measurement of its electrical properties.
Convergence Medical Devices, a start-up company
founded by Dr. Rutkove, is currently conducting a study in patients with ALS to
help further develop and refine their EIM device for the purposes of assessing
ALS in future clinical trials. The study
involves a single 45-minute visit to Convergence's headquarters in Boston, Massachusetts
where a nurse practitioner will perform basic EIM measurements on muscles in
the arm, leg, neck, and back.
For more information on this study or if you are interested
in participating, please contact Convergence Medical Devices at firstname.lastname@example.org
or call 888.382.8824 ext.108.
The facilities are wheelchair accessible and parking is
free. All participants will be
reimbursed for their time.